PMID- 33732237
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 12
DP  - 2021
TI  - Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy.
PG  - 613492
LID - 10.3389/fimmu.2021.613492 [doi]
LID - 613492
AB  - Dendritic cells (DCs) are a type of an antigen-presenting cell which undertake a 
      job on capturing antigens coming from pathogens or tumors and presenting to T 
      cells for immune response. The metabolism of DCs controls its development, 
      polarization, and maturation processes and provides energy support for its 
      functions. However, the immune activity of DCs in tumor microenvironment (TME) is 
      inhibited generally. Abnormal metabolism of tumor cells causes metabolic changes 
      in TME, such as hyperglycolysis, lactate and lipid accumulation, acidification, 
      tryptophan deprivation, which limit the function of DCs and lead to the 
      occurrence of tumor immune escape. Combined metabolic regulation with 
      immunotherapy can strengthen the ability of antigen-presentation and T cell 
      activation of DCs, improve the existing anti-tumor therapy, and overcome the 
      defects of DC-related therapies in the current stage, which has great potential 
      in oncology therapy. Therefore, we reviewed the glucose, lipid, and amino acid 
      metabolism of DCs, as well as the metabolic changes after being affected by TME. 
      Together with the potential metabolic targets of DCs, possible anti-tumor 
      therapeutic pathways were summarized.
CI  - Copyright (c) 2021 Peng, He, Huang, Tao and Liu.
FAU - Peng, Xin
AU  - Peng X
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - He, Youe
AU  - He Y
AD  - Department of Translational Medicine, Cancer Biological Treatment Center, Xiangya 
      Hospital, Central South University, Changsha, China.
AD  - Institute of Medical Sciences, Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Huang, Jun
AU  - Huang J
AD  - Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Tao, Yongguang
AU  - Tao Y
AD  - Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, 
      Department of Pathology, Xiangya Hospital, Central South University, Changsha, 
      China.
AD  - Key Laboratory of Carcinogenesis of Ministry of Health, Cancer Research 
      Institute, School of Basic Medicine, Central South University, Changsha, China.
AD  - Hunan Key Laboratory of Tumor Models and Individualized Medicine, Department of 
      Thoracic Surgery, Second Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Liu, Shuang
AU  - Liu S
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      China.
AD  - Institute of Medical Sciences, Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Department of Oncology, Institute of Medical Sciences, National Clinical Research 
      Center for Geriatric Disorders, Xiangya Hospital, Central South University, 
      Changsha, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210224
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Amino Acids)
RN  - 0 (Biomarkers)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Amino Acids/metabolism
MH  - Animals
MH  - Biomarkers
MH  - Dendritic Cells/*immunology/*metabolism
MH  - Disease Management
MH  - Disease Susceptibility
MH  - *Energy Metabolism
MH  - Glucose/metabolism
MH  - Humans
MH  - Hypoxia/genetics/metabolism
MH  - Immunotherapy
MH  - Lipid Metabolism
MH  - Neoplasms/*immunology/*metabolism/pathology/therapy
MH  - Signal Transduction
MH  - Tumor Microenvironment/*immunology
PMC - PMC7959811
OTO - NOTNLM
OT  - amino acid
OT  - dendritic cells
OT  - glucose
OT  - lipid
OT  - metabolism
OT  - therapy
OT  - tumor microenvironment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/03/19 06:00
MHDA- 2021/07/06 06:00
PMCR- 2021/01/01
CRDT- 2021/03/18 06:47
PHST- 2020/10/02 00:00 [received]
PHST- 2021/01/25 00:00 [accepted]
PHST- 2021/03/18 06:47 [entrez]
PHST- 2021/03/19 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2021.613492 [doi]
PST - epublish
SO  - Front Immunol. 2021 Feb 24;12:613492. doi: 10.3389/fimmu.2021.613492. eCollection 
      2021.